Ranbaxy to market zonisamide capsules in United States

By Elaine Rigoli

Tampa, Fla., June 9 - Ranbaxy Pharmaceuticals, Inc. said it will market zonisamide capsules for the treatment of epilepsy in the U.S. market through a strategic partnership with Invagen Pharmaceuticals, Inc.

Invagen has received Food and Drug Administration approval for 25 mg, 50 mg and 100 mg capsules, which Ranbaxy will market.

Zonisamide capsules have total annualized sales of $170.3 million, according to a news release.

Ranbaxy Pharmaceuticals, based in Jacksonville, Fla., is a wholly owned subsidiary of Ranbaxy Laboratories Ltd. in India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.